Background-Prior to implementing screening programs for acute HIV infection in developing countries, key issues including cost, feasibility, and public health impact must be determined. We compared fourth-generation enzyme immunoassay (EIA) with pooled HIV-1 RNA assays for the detection of acute and early HIV infection in counseling and testing populations in Lima, Peru.
Introduction
Screening for acute and recent HIV infection provides new opportunities for HIV treatment and prevention. Nucleic acid analysis is the gold standard for diagnosing acute and recent HIV infection, though the technical requirements often exceed developing country resources.
(1-5) Fourth-generation EIA (which adds a p24 antigen component to the third generation antibody assay) is also effective in detecting acute and recent HIV infection and adaptable to the existing infrastructure of many developing areas. (6) We report the results of a pilot program to screen for acute and recent HIV infection in Lima, Peru, comparing pooled HIV-1 RNA nucleic acid analysis and fourth generation EIA with the standard of care third generation EIA/LIA testing algorithm. 
Methods

Results
1,391 men and women requested HIV testing during the study period. 1,191 (85.6%) consented to an additional blood draw to screen for acute or recent HIV infection. (Figure 1) The prevalence of HIV infection in the study population was 3.2% (38/1191; 95% Confidence Interval [CI] = 2.2-4.2%) and the prevalence of acute or recent infection was 0.2% (2/1191; CI = 0-0.4%). The prevalence of HIV among MSM was 10.6% (25/237; CI = 6.6-14.5%), including both cases of acute or recent infection (2/237; 0.8%, CI = 0-2.0%). Compared with the standard of care EIA/LIA algorithm, fourth generation EIA with RNA PCR confirmation increased the frequency of HIV diagnosis by 5.3% (CI = 0-12.3%) overall and by 8.0% (CI = 0-18.6%) among MSM.
Discussion
In our evaluation of 1,191 men and women, we identified two cases of acute or recent HIV infection that would not have been diagnosed using Peru's standard of care screening and confirmation algorithm. While HIV-1 RNA and fourth generation EIA assays were both effective in screening for acute or recent infection, there were significant differences of cost and complexity associated with the different assays. Implementation of RNA-based testing requires substantial investments in training and infrastructure while the technical demands of fourth-generation EIA are similar to currently used assays. In contrast, while RNA PCR can screen for and confirm HIV infection, fourth generation EIA is not as specific and often requires an additional confirmatory assay for definitive diagnosis. The introduction of rapid fourth generation assays and EIAs that differentiate the presence of HIV p24 antigen from IgG/IgM antibody may contribute to use of fourth generation EIA as a single screening and confirmation assay.
The small number of participants in our pilot study limits any conclusions regarding the sensitivity or specificity of the different assays. Our inclusion of specimens positive by fourth generation EIA but negative or indeterminate by LIA in the pooled nucleic acid analysis algorithm may have increased costs compared with individual RNA testing of these specimens. Finally, recent modification of Peruvian HIV testing protocols to include rapid antibody testing could alter the context and utility of screening for acute and recent HIV infection in the country.
Our findings establish the acceptability and performance of fourth-generation EIA and pooled HIV-1 RNA PCR assays for the diagnosis of acute and recent HIV infections within a resource-limited public health system and identify a high prevalence of acute and recent HIV seroconversion among MSM in Peru. Future public health efforts should address costeffective methods to increase detection of acute and recent infection among MSM in Latin America. 
